Here, the autophagy activator RAPA was encapsulated within red blood cell membrane vesicles and modified their surface with SS31 peptide, creating SCM@RAPA biomimetic nanoparticles (NPs) capable of targeting brain tissues for possible autism therapy (Figure 1). This evidence concerns the gene TRERF1 and autism.